Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Amortization of Deferred Charges (2019 - 2024)

Serina Therapeutics' Amortization of Deferred Charges history spans 6 years, with the latest figure at -$173000.0 for Q4 2024.

  • For Q4 2024, Amortization of Deferred Charges changed N/A year-over-year to -$173000.0; the TTM value through Sep 2025 reached -$173000.0, down 151.34%, while the annual FY2024 figure was $164000.0, N/A changed from the prior year.
  • Amortization of Deferred Charges for Q4 2024 was -$173000.0 at Serina Therapeutics, down from $8000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.1 million in Q1 2023 and bottomed at -$2.0 million in Q3 2023.
  • The 5-year median for Amortization of Deferred Charges is $270000.0 (2021), against an average of $258000.0.
  • The largest annual shift saw Amortization of Deferred Charges surged 468.09% in 2021 before it plummeted 328.18% in 2023.
  • A 5-year view of Amortization of Deferred Charges shows it stood at $210000.0 in 2020, then soared by 40.0% to $294000.0 in 2021, then skyrocketed by 211.56% to $916000.0 in 2022, then plummeted by 315.72% to -$2.0 million in 2023, then surged by 91.24% to -$173000.0 in 2024.
  • Per Business Quant, the three most recent readings for SER's Amortization of Deferred Charges are -$173000.0 (Q4 2024), $8000.0 (Q3 2024), and $307000.0 (Q2 2024).